Literature DB >> 19199958

Recombinant DNA technologies for construction of precisely designed transgene constructs.

Masato Ohtsuka1, Minoru Kimura, Masafumi Tanaka, Hidetoshi Inoko.   

Abstract

Genetically modified animals have been used as models in broad range of studies including pharmaceutical biology. Designing and construction of transgene constructs are the first indispensable task in generating model animals. In addition to the classical restriction enzyme-based method, still holds some advantages in generating precise constructs, site-specific recombinase-based and homologous recombination-based DNA engineering strategies (e.g. Gateway and Red/ET recombineering, respectively) have been developed and widely used for vector construction or BAC modification. In this review, the three construction methods are described and their applications are discussed such as tandem assemblies of multiple components and modification of large DNA molecules. Combinational use of these E. coli-based recombinant DNA technologies enables the generation of precisely designed vectors useful for desired genome modification for future analyses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199958     DOI: 10.2174/138920109787315033

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  10 in total

Review 1.  Homologous recombination in human embryonic stem cells: a tool for advancing cell therapy and understanding and treating human disease.

Authors:  Andrew D Leavitt; Isla Hamlett
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

2.  Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.

Authors:  Emilie Degagné; Ashok Pandurangan; Padmavathi Bandhuvula; Ashok Kumar; Abeer Eltanawy; Meng Zhang; Yuko Yoshinaga; Mikhail Nefedov; Pieter J de Jong; Loren G Fong; Stephen G Young; Robert Bittman; Yasmin Ahmedi; Julie D Saba
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

Review 3.  Cell-Based Assay Design for High-Content Screening of Drug Candidates.

Authors:  Gregory Nierode; Paul S Kwon; Jonathan S Dordick; Seok-Joon Kwon
Journal:  J Microbiol Biotechnol       Date:  2016-02       Impact factor: 2.351

Review 4.  Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts.

Authors:  Kenneth B Gagnon; Eric Delpire
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

5.  Proteomic analysis of murine Piwi proteins reveals a role for arginine methylation in specifying interaction with Tudor family members.

Authors:  Vasily V Vagin; James Wohlschlegel; Jun Qu; Zophonias Jonsson; Xinhua Huang; Shinichiro Chuma; Angelique Girard; Ravi Sachidanandam; Gregory J Hannon; Alexei A Aravin
Journal:  Genes Dev       Date:  2009-07-07       Impact factor: 11.361

6.  Rapid bacterial artificial chromosome modification for large-scale mouse transgenesis.

Authors:  Shiaoching Gong; Laura Kus; Nathaniel Heintz
Journal:  Nat Protoc       Date:  2010-09-30       Impact factor: 13.491

7.  An asymmetric PCR-based, reliable and rapid single-tube native DNA engineering strategy.

Authors:  Yanzhen Bi; Xianfeng Qiao; Zaidong Hua; Liping Zhang; Ximei Liu; Li Li; Wenjun Hua; Hongwei Xiao; Jingrong Zhou; Qingxin Wei; Xinmin Zheng
Journal:  BMC Biotechnol       Date:  2012-07-06       Impact factor: 2.563

Review 8.  BACs as tools for the study of genomic imprinting.

Authors:  S J Tunster; M Van De Pette; R M John
Journal:  J Biomed Biotechnol       Date:  2010-12-13

9.  How genomics has informed our understanding of the pathogenesis of osteoporosis.

Authors:  Mark L Johnson; Nuria Lara; Mohamed A Kamel
Journal:  Genome Med       Date:  2009-09-07       Impact factor: 11.117

10.  A modular toolset for recombination transgenesis and neurogenetic analysis of Drosophila.

Authors:  Ji-Wu Wang; Erin S Beck; Brian D McCabe
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.